Compare Core Scientific Inc (CORZ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Recursion Pharmaceuticals Inc — how do they compare? Core Scientific Inc trades at $15.41 (market cap $4.94B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Core Scientific Inc is far larger — about 2.3× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| CORZ | RXRX | |
|---|---|---|
Market Cap | $4.94B | $2.14B |
Volume | 15,630,800 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $29.16 | $6.79 |
52-Week Low | $13.57 | $2.84 |
Typical Hold Time | 20 Days | 23 Days |
Enterprise Value | $7.46B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $15.36, down 3.64% on the day, with bearish technical signals and negative earnings momentum. The company reported a net loss of $288.62 million in 2025 with revenue of $319.02 million, resulting in a -324.9% net income margin. Despite financial challenges, analyst sentiment remains overwhelmingly positive with 19 buy ratings and a $32.75 consensus price target, representing significant upside potential from current levels.
The stock presents a high-risk, high-reward opportunity with strong Wall Street support but substantial fundamental challenges. Positive catalysts include the AI data center transition and insider buying, while risks include persistent losses, heavy capital expenditures, and competitive pressures in the digital infrastructure space.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
